50% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
Anticoagulation Forum shared on LinkedIn:
”Did you know? Up to 50% of DOAC doses are inappropriate in older adults—with underdosing being more common than overdosing.
Underdosing can actually increase the risk of stroke, systemic embolism, and cardiovascular hospitalizations, without reducing bleed risk.
This new resource, Clinical Considerations: Anticoagulation Use in Older Adults, provides practical guidance on:
- Dosing best practices
- Managing fall risk
- Addressing modifiable bleeding risk factors
- Choosing the right anticoagulant through individualized, shared decision-making
Read the full resource here.
Then, test your knowledge with our Show You Know Quiz and see how your clinical decision-making stacks up.
This resource was made possible through our collaboration with the American Pharmacists Association (APhA), with support from an educational grant by the Bristol Myers Squibb and Pfizer Alliance.
Special thanks to our expert content developers and reviewers: Christina Bookwalter PharmD, MS MEd, BCPS, BCACP, Stacey Kaplon, PharmD, BCACP, Katie Meyer, PharmD, BCPS, BCGP, Amanda McFee Winans, PharmD, BCPS, CACP.”
Stay informed on the latets in the field of anticoagulation with Hemostasis Today.
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report
-
Dec 11, 2025, 12:12Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years